Researchers have found that BMI does not predict adverse outcome in prostate cancer patients following radical prostatectomy (RP).
Jesco Pfitzenmaier, MD, PhD, and colleagues at the University of Heidelberg in Germany studied 620 prostate cancer patients who underwent RP. The men had a median age of 64.4 years and median follow-up of 5.5 years.
The investigators divided the men into three weight categories based on BMI: normal weight (25 kg/m2 or less), overweight (greater than 25 and up to 30), and obese (greater than 30).
The investigators identified organ-confined prostate cancer in 53.7%, 57.1%, and 58.6% of normal weight, overweight, and obese men, respectively, and lymph metastases in 7.9%, 7.6%, and 4.6%, according to a report in BJU International (2009;103:877-882).
These between-group differences were not statistically significant. Moreover, the three BMI groups showed no statistically significant differences in PSA recurrence-free, cancer-specific, and overall survival.
The preoperative median PSA levels were 9.0, 8.9, and 9.2 ng/L for the normal weight, overweight, and obese men, respectively.